These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 10611346)

  • 1. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.
    Davey RT; Bhat N; Yoder C; Chun TW; Metcalf JA; Dewar R; Natarajan V; Lempicki RA; Adelsberger JW; Miller KD; Kovacs JA; Polis MA; Walker RE; Falloon J; Masur H; Gee D; Baseler M; Dimitrov DS; Fauci AS; Lane HC
    Proc Natl Acad Sci U S A; 1999 Dec; 96(26):15109-14. PubMed ID: 10611346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.
    Porter BO; Anthony KB; Shen J; Hahn B; Keh CE; Maldarelli F; Blackwelder WC; Lane HC; Kovacs JA; Davey RT; Sereti I
    AIDS; 2009 Jan; 23(2):203-12. PubMed ID: 19098490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.
    Davey RT; Murphy RL; Graziano FM; Boswell SL; Pavia AT; Cancio M; Nadler JP; Chaitt DG; Dewar RL; Sahner DK; Duliege AM; Capra WB; Leong WP; Giedlin MA; Lane HC; Kahn JO
    JAMA; 2000 Jul; 284(2):183-9. PubMed ID: 10889591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs.
    Fraser C; Ferguson NM; Ghani AC; Prins JM; Lange JM; Goudsmit J; Anderson RM; de Wolf F
    AIDS; 2000 Apr; 14(6):659-69. PubMed ID: 10807189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV DNA and immune alteration during successful HAART.
    Mamadou D; Yu-Huang Z; Xia C; Bo H; Hua-Ying Z; Yan H; Zi C; Qing L; Li-Wen Z; Mei H; Yun-Hai Y; Demba S; Aldebert D; Souleymane M
    Curr HIV Res; 2013 Jun; 11(4):255-62. PubMed ID: 23822818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover.
    Anthony KB; Yoder C; Metcalf JA; DerSimonian R; Orenstein JM; Stevens RA; Falloon J; Polis MA; Lane HC; Sereti I
    J Acquir Immune Defic Syndr; 2003 Jun; 33(2):125-33. PubMed ID: 12794543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia.
    Wendland T; Furrer H; Vernazza PL; Frutig K; Christen A; Matter L; Malinverni R; Pichler WJ
    AIDS; 1999 Oct; 13(14):1857-62. PubMed ID: 10513643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
    Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
    Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
    Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
    AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients.
    Ibáñez A; Puig T; Elias J; Clotet B; Ruiz L; Martínez MA
    AIDS; 1999 Jun; 13(9):1045-9. PubMed ID: 10397534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.
    Kousignian I; Abgrall S; Duval X; Descamps D; Matheron S; Costagliola D;
    J Acquir Immune Defic Syndr; 2003 Sep; 34(1):50-7. PubMed ID: 14501793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.
    Chun TW; Engel D; Mizell SB; Hallahan CW; Fischette M; Park S; Davey RT; Dybul M; Kovacs JA; Metcalf JA; Mican JM; Berrey MM; Corey L; Lane HC; Fauci AS
    Nat Med; 1999 Jun; 5(6):651-5. PubMed ID: 10371503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
    Ruiz L; Martinez-Picado J; Romeu J; Paredes R; Zayat MK; Marfil S; Negredo E; Sirera G; Tural C; Clotet B
    AIDS; 2000 Mar; 14(4):397-403. PubMed ID: 10770542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
    Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
    J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells.
    Gray CM; Lawrence J; Ranheim EA; Vierra M; Zupancic M; Winters M; Altman J; Montoya J; Zolopa A; Schapiro J; Haase AT; Merigan TC
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1357-69. PubMed ID: 11018855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.